Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China
Location status: Recruiting
NCT Number: NCT06197724
The goal of this multi-center observational study is to learn about the effectiveness of magnetocardiography in rapid and accurate identification of ischemia in patients with suspected NSTE-ACS.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Jinan, Shandong, 250012, China
Location status: Recruiting
Rapid and accurate Identification of ischemia in patients with chest pain suspected of non-ST-elevation-acute coronary syndrome (NSTE-ACS) is of great clinical significance for timely and effective treatment. Magnetocardiography based on spin-exchange relaxation-free (SERF) principle can detect the weak magnetic field generated by the heart sensitively, which do not need ultra-low temperature cooling. Magnetic signal does not decay through the skin and tissues as electricity does, hence magnetocardiogram (MCG) contains more information of diagnostic value of ischemia. The aim of this observational study is to optimize and validate MCG models as a fast and accurate strategy for detecting coronary ischemia, as a shortage of blood supply to myocardium, in patients who suffer from chest pain, and compare to routine diagnostic means.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Magnetocardiography
Time frame: from the date of enrollment until the date of discharge, up to 30 days
the sensitivity and specificity of MCG to detect coronary ischemia (defined as stenosis ≥ 90% or fractional flow reserve ≤0.8)
Time frame: from the date of enrollment until the date of discharge, up to 30 days
A normal ECG is determined by two cardiologists with over five years of working experience. If there is any objection, the decision shall be made by a third cardiologist of the same qualifications or above. Sensitivity, specificity, and area under ROC curve (AUC) are performed for assessing the efficacy.
Time frame: from the date of enrollment until the date of discharge, up to 30 days
The time for the detection of NSTEMI is from the timepoint of first medical contact to the timepoint of MCG report showing ischemia or the first report of troponin that over the 99th percentile of the Upper reference limit (URL).
Time frame: from the date of enrollment until the date of discharge, up to 30 days
The severity of coronary lesions is determined by using CAG/CTA and fractional flow reserve. Severe degree is defined as ≥90% stenosis of at least one main vessel or branch vessel with diameter ≥2mm. Moderate degree is defined as 50%-89% stenosis and fractional flow reserve ≤0.8. Mild degree is defined as <50% stenosis and fractional flow reserve ≤0.8, or stenosis 50%-89% and fractional flow reserve> 0.8. Sensitivity, specificity, and area under ROC curve (AUC) are performed for assessing the efficacy.
Time frame: from the date of enrollment until the date of discharge, up to 30 days
For early stratification measurement, patients with suspected NSTE-ACS are assessed by 30d (from enrollment) MACE and classified as high or low risk. Sensitivity, specificity, and area under ROC curve (AUC) are performed for assessing the efficacy of MCG.
Contact information is provided by the study sponsor or research team.
Qilu Hospital of Shandong University
Other
Magnetocardiography as an Innovative Diagnostic Tool for Early and Accurate Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06695429
Contrast Induced Nephropathy, Non ST Segment Elevation Acute Coronary Syndrome
Cartagena, Spain
View Trial DetailsNCT06255678
Acute Coronary Syndrome, Cardiovascular Diseases
Warsaw, Poland
View Trial DetailsNCT06051110
Acute Coronary Syndrome, Cardiovascular Diseases
Eindhoven, Netherlands
View Trial DetailsNCT07252245
Non ST Segment Elevation Acute Coronary Syndrome
Nijmegen, Netherlands
View Trial Details